NCATS Drug Substance Development and Manufacture

IDIQ

Description

Support the DPI drug development program by contracting for Chemistry, Manufacturing, and Control services. Specifically, this proposed project is designed to ensure DPI receives Active Pharmaceutical Ingredients and formulated Drug Product of sufficient quality and quantity to support IND-enabling, pre-clinical, and clinical studies. Services provided include:
(1) Manufacture and Analysis of Small Molecules;
(2) Manufacture and Analysis of Synthetic Peptides, Oligonucleotides, and Related Substances; and
(3) Manufacture and Analysis of Biopharmaceuticals.

Overview

Ceiling

$24,598,861

Primary Sponsoring Agency

National Institute on Drug Abuse (NIDA) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

325411 - Medicinal and Botanical Manufacturing

Primary PSC

AN11 - Health R&D Services; Health Care Services; Basic Research

Primary Set Aside

None

Extent Competed

Full And Open Competition

Related Opportunity

CRO Support for NCATS Drug Substance Development and Manufacture (N01TR-17-2001)

NCATS Drug Substance Development and Manufacture awarded by National Institute on Drug Abuse (NIDA) in March 2017 accepts orders through March 2022. The IDIQ has a reported ceiling of $24,598,861, and as of today, $12,645,815 has been obligated through the vehicle with a total reported backlog of $1,156,279. The IDIQ was awarded full & open and has a primary NAICS code of 325411.

Award Hierarchy

Vehicle

NCATS Drug Substance Development and Manufacture

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

3/30/17

Start Date

3/31/22

Ordering Period End Date

100% Complete

Task Order Obligations and Backlog

$12.6M

Total Obligated

$12.6M

Current Award

$13.8M

Potential Award

92% Funded

$0.0

Funded Backlog

$1.2M

Total Backlog

Vehicle Award Share

Contractors with greatest percentage of obligations for NCATS Drug Substance Development and Manufacture

Vehicle Award Share

Federal Award Analysis